Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Amphastar Pharmaceuticals, Inc.'s Expenses

Vertex vs. Amphastar: A Decade of Cost Evolution

__timestampAmphastar Pharmaceuticals, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 201415920500060987000
Thursday, January 1, 2015174172000125542000
Friday, January 1, 2016150976000210460000
Sunday, January 1, 2017149380000275119000
Monday, January 1, 2018187681000409539000
Tuesday, January 1, 2019190434000547758000
Wednesday, January 1, 2020206506000736300000
Friday, January 1, 2021238029000904200000
Saturday, January 1, 20222501270001080300000
Sunday, January 1, 20232932740001262200000
Monday, January 1, 20241530500000
Loading chart...

Cracking the code

Cost Insights: A Comparative Analysis of Vertex and Amphastar Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Vertex Pharmaceuticals Incorporated and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Vertex Pharmaceuticals has seen a staggering increase in its cost of revenue, growing by over 1,900%, from approximately $61 million in 2014 to $1.26 billion in 2023. This reflects Vertex's aggressive expansion and investment in research and development. In contrast, Amphastar Pharmaceuticals experienced a more modest growth of around 84%, with costs rising from $159 million to $293 million. This steady increase highlights Amphastar's consistent operational strategy. The data underscores the contrasting growth trajectories and strategic priorities of these two pharmaceutical giants, offering valuable insights for market analysts and investors.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025